Tag Archives | BIO ETF’s

Biotechs Unhinged by Tough Pricing Talk

Biotechs Unhinged-Roiled by Commentary and Tweet storms Biotech stocks rallied briefly early in the week but sold off abruptly over the past two days with a quote from Trump in a Time Person of the Year article as saying, “I’m going to bring down drug prices”. This tough talk is reminiscent of comments by both […]

Continue Reading 0

Biotech Stocks Recovering from Last Week’s Free Fall: XBI…Update-2

Green Tape Today Shows Resilience– 10/10/16 ESMO Cancer Congress 4%+ Up movers: AGIO ARIA BLUE CLVS LGND PBYI TSRO etc. XBI up 2.39% More Bad Clinical News for Biotech:ALNY,CLVS The XBI lost 3.2% for the week to $64.15 taking a hit from Alnylam (ALNY) downdraft down 49% for the week. The IBB also took a […]

Continue Reading 0

Biotech ETFs Lead Q3 Rally: XBI Breaks Out

Biotech ETFs Are Having A Strong Quarter and Offer Good Investment Options On July 20 we did a review of active funds vs biotech ETFs in the biotechnology/life science sector just after the BREXIT lows. At that time biotech ETFs and broadly diversified funds beat the “pure play” biotechnology funds such as Fidelity Select Biotechnology Portfolio […]

Continue Reading 0

Crude Stabilizes then Biotech Turns Green: Stay Tuned But Cautious

Biotech Stocks Off  Lows Tracking Crude and Energy sector… 11.45 a EST Can healthcare stocks uncouple from energy and macro? Individual biotech stocks look very tradable with green catching up with red. But biotech stocks defy fundamental analysis with current random hourly volatility.  IBB up 0.12% off bottom of $254 XBI up 0.20% XLE up […]

Continue Reading 0

Biotech Bull Market Rolls On in a Volatile Q2 2015: XBI Up 12.4%

Dealmaking and Fast Money Fuel Biotechs Q2 2015 Review Despite a major down trend at the end of April and the recent sell-off, the sector outperformed in Q2 of 2015. The S&P was down 1% and flat YTD. The XBI Biotech ETF continues to be the sector ETF leader up 12.41% compared to 5% for the […]

Continue Reading 0

BIO Investor Forum Oct. 7-8, 2014: #1 How Fragile is the Biotech Rally?

Five Year Bull Market in Biotech  We attended the Bio Investor Forum in San Francisco this week and it was well attended with over 600 participants and over 120 companies presenting. Attendees included VCs , investors, industry executives, bankers, and media. The Bio Investor Forum is one of the best meetings for current issues and […]

Continue Reading 0

FED Comments Focus On “Bubble” Stocks In Social Media and Biotech…. Update-1

Update 8PM EDT NASDAQ Holds Losses to 0.54%-Futures Stable Biotech Damage Across the Sector-Rayno Life Science Portfolio Notes Large Caps off about 2% (FBT), but Gilead (GILD) down only 0.95% and Roche (RHHBY) up 0.28%. Rayno Biopharma stocks all red down 3-4% with XBI down 3.86%, IBB down 2.2%. Damage not as severe in Diagnostics […]

Continue Reading 0

Snap-Back Rally in Biotech Up 4+% Friday

Life Science Stocks Surge Ahead From February Lows  NASDAQ Up 1.67%, IBB Up 4%, FBIOX up 4.72%, XBI up 5.64%, XLV up 1.7% The soaring biotech sector would not let a losing week go by and took off early Friday erasing most losses for the week 2/3 to 2/7. Institutions can apparently drive biotech stocks […]

Continue Reading 0

Biotech Rally Update at New Highs: ETFs (IBB,PBE) Beat Five Star Fidelity Fund (FBIOX)

Up until recently the Fidelity Select Biotechnology Fund (FBIOX) has outperformed all ETFs but now the IBB and PBE are leaders over the last 3 months. There have been two recent mini-corrections but over the past two weeks the IBB has soared up almost 15% for the past 3 months.The PBE has also outperformed but the […]

Continue Reading 0

Biotechnology Bull Market Gets Second Wind To All Time Highs: ALR, GILD, ILMN,

Dow, S&P and Biotech Sector Hit All Time Highs NASDAQ Still 1000+Pts Under 2000 High Levels After a 10% sell-off in early October many large cap biopharmaceutical and diagnostic stocks are at new highs with the major indices at or near their October highs. The bellwether ETF IBB ($211.30) is flat after the index was […]

Continue Reading 0